Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SMAD2 binding regions in estrogen receptor-positive breast cancer cell line, T47D

ABSTRACT: SMAD2 binding regions in estrogen receptor-positive breast cancer cell line, T47D

PROVIDER: PRJNA482344 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7550970.fastq.gz	Fastqsanger.gz
	SRR7550971.fastq.gz	Fastqsanger.gz
	SRR7550972.fastq.gz	Fastqsanger.gz
	SRR7550973.fastq.gz	Fastqsanger.gz
	SRR7550969.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 5

Similar Datasets

SMAD2 binding regions in estrogen receptor-positive breast cancer cell line, T47D

Project description:Inhibitors for cyclin-dependent kinase (CDK) 4 and CDK6 have been established as effective therapeutic options for hormone receptor (HR)-positive, HER2-negative advanced breast cancer. Although the CDK4/6 inhibitors mainly target the cyclin D-CDK4/6-retinoblastoma tumor suppressor protein (RB) axis, little is known about clinical impact of inhibiting phosphorylation of other CDK4/6 target proteins. Here, we have focused on other CDK4/6 targets, SMAD proteins. We showed that a CDK4/6 inhibitor Palbociclib and Activin-SMAD2 signaling cooperatively inhibited cell cycle progression of a luminal-type breast cancer cell line T47D. Mechanistically, Palbociclib enhanced SMAD2 binding to the genome through inhibiting linker phosphorylation of the SMAD2 protein by CDK4/6. Comparison of the SMAD2 ChIP-seq data of T47D with those of a triple-negative breast cancer cell line Hs578T indicated that Palbociclib augments different SMAD2-mediated program defined based on types of cells, and enhances SMAD2 binding to the target regions on the genome without affecting its binding pattern. Collectively, the CDK4/6 inhibitor facilitates the cytostatic effects of Activin-SMAD2, while it also enhances its tumor promoting effects depending on types of breast cancer.

2018-10-23 | GSE117495 | GEO

SMAD2 binding regions in triple negative breast cancer cell line, Hs578T

2018-10-23 | GSE117496 | GEO

SMAD2 binding regions in breast cancer cell line and RNA-seq transcriptome analyses in T47D

Project description:SMAD2 binding regions in breast cancer cell line and RNA-seq transcriptome analyses in T47D

| PRJNA482337 | ENA

Nascent RNA sequencing (PRO-seq) after estrogen treatment in T47D cells

Project description:This experiment identifies the primary estrogen response genes in T47D cells.

2021-09-17 | GSE184378 | GEO

Smad2/3 binding regions in NMuMG cells

Project description:Smad2/3 binding regions in NMuMG cells

| PRJNA496488 | ENA

Estrogen receptor agonism/antagonism in T47D cells

Project description:Estrogen receptor agonism/antagonism in T47D cells

| PRJNA1055455 | ENA

RNA-seq transcriptome analyses in T47D cells treated with ActA and Palbociclib.

Project description:We performed SMAD2 ChIP-seq analysis in T47D cells with/without Palbociclib treatment. To validate whether the changes in SMAD2 binding to the genome indeed resulted in changes in target gene expression, we performed RNA-seq transcriptome analyses in T47D with/without ActA stimulation and Palbo treatment.

2018-10-23 | GSE117497 | GEO

Smad2/3 binding regions in NMuMG cells

Project description:Smad2/3 binding regions in mouse mammary gland epithelial cells (NMuMG) treated with TGF-beta for 1.5 h were determined by ChIP-seq to evaluate the transcriptional mechanism of TGF-beta-Smad signaling.

2019-08-29 | GSE121254 | GEO

Differential expression levels of mRNAs in tamoxifen-sensitive T47D versus tamoxifen-resistant T47D (T47DR) human breast cancer cells

Project description:Tamoxifen is the most widely used antiestrogen in patients with estrogen receptor (ER) positive breast cancer . However, less than half of patients benefit from tamoxifen treatment and 30-50% acquire resistance and the disease progresses. Resistance to tamoxifen is a serious problem in breast cancer therapy and major efforts are underway to find out underlying mechanisms. To find out the differential expression levels of mRNAs in tamoxifen-sensitive T47D versus tamoxifen-resistant T47D (T47DR) human breast cancer cells, T47DR (tamoxifen-resistant) cell line was established from T47D cells after the following continuous exposure to 1 μmol/L 4-Hydroxytamoxifen (H7904, Sigma, USA) for more than 6 months.Thousands of significantly different mRNA expression levels were found and analysed. Our study provides a reference data for the study of tamoxifen resistance .

2020-06-01 | GSE129544 | GEO

Anti-cancer effects of 7-oxabicyclo[2.2.1]heptene sulfonamide (OBHSA) derivative 17e on gene expression of breast cancer T47D cells

Project description:To investigate the anti-cancer effects of PROTAC-like OBHSA derivative 17e, we exposed estrogen receptor alpha positive (ERα+) breast cancer cell line T47D to compound 17e at 10 μM for 12 hours . We then performed gene expression profiling analysis using data obtained from RNA-seq of T47D cells treated with DMSO or 17e (10 μM) in three replicates.

2024-06-18 | GSE210169 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data